Status:
COMPLETED
Midodrine for the Early Liberation of Vasopressor Support in the ICU
Lead Sponsor:
University of Alberta
Collaborating Sponsors:
Alberta Health services
Institute of Health Economics, Canada
Conditions:
Critical Illness
Shock
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Vasopressors are medications that are given intravenously to increase the blood pressure of patients with illnesses that cause dangerous blood pressure drops. When a doctor prescribes a vasopressor, t...
Detailed Description
Purpose: Resuscitation and hemodynamic support with intravenous (IV) vasopressors is a prime indication of treatment in intensive care unit (ICU) settings. Hemodynamic support is typically provided wi...
Eligibility Criteria
Inclusion
- Age \> 18 years old
- ICU admission
- Ongoing vasopressor support
- Decreasing vasopressor dose
Exclusion
- Greater than 24 hours from peak vasopressor dose
- Contraindication to enteral medications
- Previously on midodrine in last 7 days
- Expected death or withdrawal of life-sustaining therapies
- Pregnancy
- Known allergy to Midodrine
Key Trial Info
Start Date :
March 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04489589
Start Date
March 22 2021
End Date
October 30 2022
Last Update
October 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta Hospital
Edmonton, Alberta, Canada, T5R0T1